Incyte Drug Misses Endpoint in COVID-Respiratory-Distress Trial

Incyte (INCY) shares were higher on Friday after the biopharma said that in a clinical trial its ruxolitinib missed its key endpoint of preventing deaths among patients with COVID-19-related acute respiratory distress syndrome.